Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment
Autor: | Yao Ding, Rolin L Wade, Dionne M. Hines, Anne Beaubrun, Joshua Cohen |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
Younger age Index date business.industry Treatment adherence Health Policy 05 social sciences Human immunodeficiency virus (HIV) Medicine (miscellaneous) Pharmacy medicine.disease_cause 0506 political science Persistence (computer science) Discontinuation 03 medical and health sciences Regimen 0302 clinical medicine Internal medicine 050602 political science & public administration medicine 030212 general & internal medicine business Pharmacology Toxicology and Pharmaceutics (miscellaneous) Social Sciences (miscellaneous) |
Zdroj: | Patient Preference and Adherence. 13:1927-1939 |
ISSN: | 1177-889X |
DOI: | 10.2147/ppa.s207908 |
Popis: | Objective To assess adherence and persistence with first-line single-tablet regimen (STR) and multi-tablet regimen (MTR) antiretroviral therapy (ART) in newly treated HIV-1 patients. Methods Retrospective analysis of longitudinal pharmacy claims among US patients initiating ART between 1/1/2016 and 5/31/2016 (index date was defined by first ART claim for STRs, and fill date for the last therapy in the regimen for MTRs). Adherence was assessed over a 12-month period and reported as the proportion of adherent or non-adherent (defined as ≤5-day and > a 5-day gap between successive fills, respectively) patients. Sensitivity analysis using ≤7-day and ≤14-day gap thresholds to define adherence was performed. Persistence was assessed as the number of days on therapy from index until treatment discontinuation (>90 day gap in therapy). Kaplan-Meier curves and Cox Proportional Hazard models were generated to evaluate discontinuation rates. Assessments were performed on STRs vs MTRs overall and by regimen. Results Patients initiating ART (STR: n=10,623; MTR: n=2504) had a mean age of 42.8 years; 76.0% were male. STR patients were >2 times more likely to be adherent over 12 months than MTR patients (24.9% vs 11.7%, respectively). Patients using EVG/COBI/FTC/TAF had greater adherence than those using other STRs. Among MTRs, patients were more adherent with FTC/TDF+DTG (15.1%) than other MTRs. Persistence was also greater with STRs, with MTR patients being 61% more likely to discontinue therapy. Persistence was best for FTC/TAF-based regimens. Predictors of treatment discontinuation included younger age, female gender, and Medicare or Medicaid insurance type. Conclusion Patients receiving STRs were significantly less likely to discontinue therapy and were more adherent with their regimens, providing further evidence of greater adherence and persistence with STRs versus MTRs. However, there was a large proportion of patients who interrupted or discontinued treatment. Further research examining treatment patterns beyond first line is warranted. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |